Bal Pharma enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


137	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
4.4	4.4	4.2	11.0	1.5
0.0	0.0	−0.0	−0.0	−0.1
160	160	150	140	131
292	—	—	—	—
155	155	146	129	130
₹183.63	—	—	—	—

242	242	228	209	195
66.0%	66.0%	66.0%	66.8%	67.3%
0.55×	—	—	—	—

0.87×	—	—	—	—
8.65×	—	—	—	—
13.02×	—	—	—	—
23.81×	—	—	—	—
334	312	303	339	304
33.8	31.9	29.6	31.5	25.1
22.4	20.8	19.8	21.5	16.0
—	30.8	20.7	329	23.0
12.3	12.3	20.7	329	23.0
—	12.3	20.7	343	17.6
—	18.6	0.0	0.0	0.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BALPHARMA₹86.17

Bal Pharma Limited

· Pharma & Health

₹ CrorePeersALPA KREBSBIO NATCAPSUQ VINEETLAB NECLIFE AAREYDRUGS BIOFILCHEM MANGALAMMcap ₹137 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	137.2
- Cash, Equiv & ST Investments	1.5	11.0	4.2	4.4	4.4
+ Minority Interest	-0.1	-0.0	-0.0	0.0	0.0
+ Total Debt	131.0	139.6	150.4	159.5	159.5
Enterprise Value	—	—	—	—	292.3
Net Debt (memo)	129.5	128.7	146.2	155.1	155.1
EV per Share	—	—	—	—	183.63

Total Capital	194.7	208.9	227.8	241.8	241.8
Total Debt/Total Capital	67.28	66.85	66.02	65.98	65.98
Total Debt/EV	—	—	—	—	0.55

EV/Sales	—	—	—	—	0.87
EV/EBITDA	—	—	—	—	8.65
EV/EBIT	—	—	—	—	13.02
EV/Free Cash Flow	—	—	—	—	23.81
Reference Items — Trailing FY Values
Sales	304.2	339.2	303.1	311.7	334.4
EBITDA	25.1	31.5	29.6	31.9	33.8
EBIT	16.0	21.5	19.8	20.8	22.4
Operating Cash Flow	23.0	329.2	20.7	30.8	—
Free Cash Flow	23.0	329.2	20.7	12.3	12.3
FCFF (free cash flow to the firm)	17.6	342.6	20.7	12.3	—
Capital Expenditure	0.0	0.0	0.0	18.6	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.